Hypoxia Inducible Factor-2α (HIF-2α) Pathway Inhibitors

作者
Ratika Dogra,Ulka N. Vaishampayan
出处
期刊:Journal of Kidney Cancer and VHL [Codon Publications]
卷期号:12 (3): 1-15 被引量:17
标识
DOI:10.15586/jkcvhl.v12i3.413
摘要

Hypoxia creates a stressful environment for the cells triggering adaptive changes in the transcription factors called hypoxia inducible factors (HIF), which help to meet the metabolic and angiogenic requirements of cells. HIF-2 is one such factor that is implicated in the progression of various cancers, especially the ones associated with Von Hippel–Lindau (VHL) disease. HIF-2 factor has an unstable component alpha and a stable component beta. HIF-2α detects hypoxia and dimerizes with HIF-beta (Aryl hydrocarbon receptor nuclear translocator [ARNT]) through per-ARNT-sim (PAS)-mediated signaling domains. These domain sites are recognized as targets for HIF-2 inhibitors. HIF-2 inhibitors block this heterodimerization and prevent the expression of target genes which are oncogenic, including VEGF, PDGF, CAIX, and Oct4. VHL disease caused by the deficiency of VHL gene product results in decreased degradation of HIF-2α, leading to increased activation of these transcription factors. Tumors driven by the deficiency of VHL gene product are natural candidates for HIF-2 inhibitor therapy. These inhibitors have emerged as a promising class of targeted therapies for renal cell carcinoma (RCC), particularly in cases resistant to conventional treatments. In this review, we explore the role of hypoxia and HIF transcription factors in tumor formation and progression, highlighting the role and development of HIF-2 pathway inhibitors as potential cancer therapies. We discuss the major key inhibitors, with focus on belzutifan and review the various trials investigating its efficacy in monotherapy as well as in combination therapies in RCC. Additionally, we explore its development in pheochromocytoma, hemangioblastoma, and pancreatic neuroendocrine tumors. We also highlight emerging HIF-2α inhibitors currently in clinical trials, namely casdatifan, NKT-2152, and DFF332. Finally, we address the major toxicities and management of these inhibitors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刘晨发布了新的文献求助10
刚刚
xucc发布了新的文献求助10
刚刚
在水一方的应助被syh采纳,获得10
刚刚
1秒前
王博龙完成签到,获得积分10
1秒前
2秒前
腼腆的眼睛完成签到 ,获得积分10
2秒前
hana发布了新的文献求助10
2秒前
2秒前
东方完成签到,获得积分10
2秒前
丘比特的应助被苦瓜大王采纳,获得10
2秒前
2秒前
liuis完成签到,获得积分10
3秒前
3秒前
Jasper的应助被一滩烂泥采纳,获得10
3秒前
Lotus完成签到,获得积分10
3秒前
洞洞幺发布了新的文献求助10
3秒前
大绿豆cc发布了新的文献求助10
3秒前
4秒前
忱麓裔发布了新的文献求助10
4秒前
6秒前
ke完成签到,获得积分10
6秒前
Jupiter发布了新的文献求助10
6秒前
6秒前
ypz发布了新的文献求助10
6秒前
雨天完成签到,获得积分10
6秒前
Overlap完成签到 ,获得积分10
6秒前
靓丽芙蓉完成签到,获得积分10
6秒前
islazheng发布了新的文献求助10
7秒前
7秒前
丁丁当当发布了新的文献求助10
7秒前
8秒前
李健的应助被小羊采纳,获得10
8秒前
科研通AI2S的应助被mike采纳,获得10
9秒前
YUYUYU发布了新的文献求助10
9秒前
空瓶氧气发布了新的文献求助10
10秒前
heoouijee发布了新的文献求助10
10秒前
10秒前
10秒前
Ivychang发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417